论文部分内容阅读
目的观察乙酰半胱氨酸泡腾片治疗阻塞性睡眠呼吸暂停低通气综合征(OSAHS)的临床疗效及安全性。方法将100例OSAHS患者随机分为对照组50例和试验组50例。对照组予以低流量吸氧、功能锻炼、调节饮食等常规治疗;试验组在对照组治疗的基础上,予以乙酰半胱氨酸泡腾片600 mg,qd,口服。2组患者均治疗12周。比较2组患者的临床疗效、血清内皮素-1(ET-1)、一氧化氮(NO)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)的水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为90.00%(45例/50例)和74.00%(37例/50例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的ET-1分别为(39.24±5.50)和(46.28±0.12)ng·L~(-1),NO分别为(56.25±7.05)和(48.88±5.60)μmol·L~(-1),IL-6分别为(41.48±4.91)和(65.77±9.10)ng·L~(-1),TNF-α分别为(28.37±3.42)和(42.32±6.21)ng·L~(-1),差异均有统计学意义(均P<0.05)。2组患者治疗期间均未发生药物不良反应。结论乙酰半胱氨酸泡腾片治疗OSAHS的临床效果确切,其能够有效地调节血清ET-1、NO、IL-6、TNF-α水平,且安全性较好。
Objective To observe the clinical efficacy and safety of acetylcysteine effervescent tablets in the treatment of obstructive sleep apnea-hypopnea syndrome (OSAHS). Methods 100 OSAHS patients were randomly divided into control group (50 cases) and experimental group (50 cases). The control group was given low-flow oxygen, functional exercise, diet and other routine treatment; experimental group in the control group based on the treatment, to be given acetylcysteine effervescent tablets 600 mg, qd, orally. Two groups of patients were treated for 12 weeks. The clinical efficacy, the levels of ET-1, NO, IL-6 and TNF-α were compared between the two groups. As well as the occurrence of adverse drug reactions. Results After treatment, the total effective rate was 90.00% (45 cases / 50 cases) and 74.00% (37 cases / 50 cases) in experimental group and control group, respectively. The difference was statistically significant (P <0.05). After treatment, the levels of ET-1 in the test group and the control group were (39.24 ± 5.50) and (46.28 ± 0.12) ng · L -1, respectively, and were 56.25 ± 7.05 and 48.88 ± 5.60 μmol·L -1 respectively The levels of IL-6 and IL-6 were (41.48 ± 4.91) and (65.77 ± 9.10) ng · L -1 and (28.37 ± 3.42) and (42.32 ± 6.21) ng · L L ~ (-1), the differences were statistically significant (P <0.05). Two groups of patients during the treatment did not occur adverse drug reactions. Conclusion The clinical efficacy of acetylcysteine effervescent tablets in the treatment of OSAHS is exact. It can effectively regulate the levels of ET-1, NO, IL-6 and TNF-α in serum and has good safety.